Compare · ELUT vs MRNA
ELUT vs MRNA
Side-by-side comparison of Elutia Inc. (ELUT) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELUT and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $90.35B, about 2775.4x ELUT ($32.6M).
- MRNA has been more active in the news (11 items in the past 4 weeks vs 1 for ELUT).
- MRNA has more recent analyst coverage (25 ratings vs 0 for ELUT).
- Company
- Elutia Inc.
- Moderna Inc.
- Price
- $0.77-3.49%
- $217.55-7.99%
- Market cap
- $32.6M
- $90.35B
- 1M return
- -
- +37.67%
- 1Y return
- -
- +702.18%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2018
- News (4w)
- 1
- 11
- Recent ratings
- 0
- 25
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest ELUT
- Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
- CHIEF SCIENTIFIC OFFICER Williams Michelle Leroux converted options into 12,500 shares and covered exercise/tax liability with 4,269 shares, increasing direct ownership by 7% to 126,283 units (SEC Form 4) (tax liability)
- CHIEF FINANCIAL OFFICER Ferguson Matthew converted options into 12,500 shares and covered exercise/tax liability with 4,486 shares, increasing direct ownership by 2% to 489,903 units (SEC Form 4) to cover withholding tax
- PRESIDENT AND CEO Mills C Randal converted options into 27,083 shares and covered exercise/tax liability with 9,718 shares, increasing direct ownership by 4% to 464,395 units (SEC Form 4) (tax liability)
- Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th
- Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference
- Elutia Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits
- Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.
- Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch
- SEC Form S-8 filed by Elutia Inc.
Latest MRNA
- SEC Form 4 filed by Moderna Inc.
- AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
- Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026
- SEC Form 4 filed by Moderna Inc.
- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- SEC Form 3 filed by Moderna Inc.
- Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026
- Moderna downgraded by Citigroup with a new price target
- Moderna Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Moderna Adds Chief Operating Officer Role as Company Expands into Oncology